{"id":470,"date":"2026-03-02T10:55:10","date_gmt":"2026-03-02T10:55:10","guid":{"rendered":"https:\/\/efanet.org\/annual-report\/?page_id=470"},"modified":"2026-03-04T09:52:35","modified_gmt":"2026-03-04T09:52:35","slug":"efa-care-advocacy","status":"publish","type":"page","link":"https:\/\/efanet.org\/annual-report\/2023\/care\/efa-care-advocacy\/","title":{"rendered":"EFA Care Advocacy"},"content":{"rendered":"\n

The year 2023 was very intense for the development of legislation to address unmet medical needs, ensure better patient access to treatment, to reduce medicines shortages in the EU and be prepared with medical countermeasures against treats to health. EFA collaborated with the EMA and brought the allergy, atopic eczema, asthma and COPD patient perspective and agenda to several European Commission fora.<\/p>\n\n\n\n

Shaping a future EU pharmaceutical legislation that works for patients<\/h2>\n\n\n\n

In 2023, EFA developed our allergy, atopic eczema and respiratory patients asks on the EU proposals to revise the current pharmaceutical framework, one of the most impactful legislations in health at the EU level.<\/p>\n\n\n\n

Following one EFA community strategic discussion on the proposals, and after the publication in late April of the European Commission proposals to review the pharmaceutical legislation EFA responded to the two EC final consultations<\/strong> on the Directive on medicines<\/strong>, which emphasises driving innovation and access towards medicines for children and rare disease patients, and the proposal for a Regulation<\/strong> on how medicines are incentivised, authorised, and supervised in the EU.<\/p>\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

As the legislation to be reviewed affects all patients and disease areas in Europe, EFA worked very closely with the European Patients\u2019 Forum<\/strong> (EPF). We contributed to EPF\u2019s \u2018paediatric task force\u2019 and the \u2018unmet medical needs task force\u2019, sharing in five dedicated meetings the needs and concerns from EFA communities as well as with written contributions which were then published in three EPF\u2019s papers.<\/p>\n\n\n\n

EFA\u2019s advocacy on the EU Pharmaceutical legislation in 2023<\/h4>\n\n\n\n
May<\/div>
EFA – EFA statement at EC Stakeholder dialogue on the revision of the EU Pharmaceutical legislation<\/div><\/div>
June<\/div>
EFA – EFA questions to European Commission during a closed EMA\/PCWP special webinar on the revision of the pharmaceutical legislation<\/div><\/div>
July<\/div>
EPF – A patient-centred revision of the EU pharmaceutical legislation\u2019,<\/div><\/div>
September<\/div>
EPF – Ensuring access to paediatric medicines\u2019<\/div><\/div>
October<\/div>
EPF – A patient-centred vision for unmet medical needs\u2019<\/div><\/div>
November<\/div>
EFA – Response to final consultation on the proposal for a Directive on the Union code relating to medicinal products for human use (2023\/0132)<\/div><\/div>
November<\/div>
EFA – Response to final consultation on the proposal for a Regulation on laying down procedures for the authorisation and supervision of medicinal products for human use and establishing rules for governing the European Medicines Agency (2023\/0131)<\/div><\/div><\/div>\n\n\n\n